Large Animal Models

Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform that focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs. The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients. In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process.

With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. Due to their higher physiological similarity to humans, these models are particularly valuable in the research of cardiovascular diseases, metabolic disorders, inflammatory immune diseases, and neurological diseases.
In order to assist clients in precisely selecting suitable large animal models, Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform. This platform focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs, and offers comprehensive and in-depth disease model development and pharmacodynamic research. The platform is equipped with world-class experimental facilities and equipments and is supported by a team of experienced scientists and technical experts. This professional team is dedicated to providing pharmacodynamic research services, including experimental protocal design, model establishment, and data analysis, to accelerate the translation of scientific research results into clinical applications.

Diverse Disease Models, Empowering Drug Development Innovation

The Medicilon Large Animal Pharmacodynamic Research Service Platform encompasses a wide range of disease models, including but not limited to metabolic diseases (such as obesity, diabetes, and hyperuricemia), cardiovascular diseases (such as thrombosis, stroke, and atherosclerosis), inflammatory and immune diseases (such as arthritis, osteoporosis, and psoriasis), as well as other disease models. This comprehensive coverage addresses nearly all major disease areas in current drug development.

The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients. In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process.

Table 1: Types of Large Animal Pharmacodynamic Models Conducted by Medicilon

Disease Areas	Large Animal Disease Models
Metabolic Disease Models	Obesity and Diabetes Models Hyperuricemia Models Liver Fibrosis Models Pulmonary Fibrosis Models Dyslipidemia Models Non-Alcoholic Fatty Liver Models Hepatobiliary Models
Inflammatory and Immune Disease Models	Arthritis and Osteoarthritis Models Osteoporosis Models Psoriasis Models Atopic Dermatitis Models Multiple Sclerosis Models Acute Inflammation Models
Cardiovascular Disease Models	Thrombosis and Anticoagulation Models Stroke Models Atherosclerosis Models Anemia Models
Other Disease Models	Skin Wound Models Kidney Failure and Injury Models Gynecological Disease Models

AAALAC Certification, Animal Facilities Meet International Standards

Medicilon's preclinical animal testing facility has been accredited by AAALAC International since 2009 and has consistently passed re-evaluations. The facility meets international standards in experimental animal quality, animal welfare, and biosafety.
Table 2: Current Large Animal Capacity at Medicilon
Species Number of Rooms Capacity
Non-Human Primates 61 2,260
Dogs 62 1,720
Rabbits 14 520
Miniature Pigs 10 200
Medicilon's large animal efficacy research and development service platform currently boasts spacious animal housing. From animal care and management to experimental procedures, every step strictly adheres to international standards, providing a solid foundation for large-scale, high-quality, and efficient efficacy experiments.

Species	Number of Rooms	Capacity
Non-Human Primates	61	2,260
Dogs	62	1,720
Rabbits	14	520
Miniature Pigs	10	200

Advanced Instruments and Equipment Enhance R&D Efficiency and Effectiveness

The platform is equipped with advanced large animal experimental instruments, pharmacodynamic experimental analysis equipment, and pharmacodynamic experimental pathological research devices, providing strong technical support for disease efficacy evaluation and ensuring the accuracy and reliability of the experimental process.
1. Large Animal Experimental Instruments and Equipment
2. Pharmacodynamic Experimental Analysis Equipment
3. Pharmacodynamic Experimental Pathological Research Equipment

Case Studies

Practices and Achievements of Medicilon's Large Animal Pharmacodynamic Research and Development Service Platform
Case 1: Analgesic Test of Compound Preparation on Postoperative Acute Pain Model in Bama Miniature Pigs
Case 2: The Effect of a Small Molecule Anticoagulant on the Coagulation Function of Cynomolgus Monkeys
Case 3: Efficacy Study of Acne Medication in New Zealand Rabbits
Case 4: IVGTT and Insulin Testing in Cynomolgus Monkeys
Case 5: Weight Loss Experiment in Cynomolgus Monkeys
In the ever-evolving wave of the biopharmaceutical field, Medicilon's large animal efficacy research and development service platform adheres to the principles of innovation leadership, openness, and collaborative win-win strategies. The platform continuously deepens the expansion of its functions and service boundaries. The platform will actively explore new methods and technologies for constructing disease models, continuously enriching and developing models for neurological disorders, inflammatory and immune diseases, cardiovascular and metabolic disorders, digestive system diseases, ocular diseases, and other conditions. This aims to provide clients with more precise, efficient, and comprehensive drug development solutions.